|
|
|
| Registros recuperados: 13 | |
|
|
| Abdallah,N; Morsi,M; Hamed,N; Abdel Aziz,H. |
| The most reliable determination of severity and prognosis in chronic viral hepatitis is the histological staging of the disease, which comprises an invasive procedure and is often not well accepted by patients. The search for alternative non-invasive methods is mandatory especially in follow-ups after initial assessment by biopsy. The aim of this study was to evaluate the role of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) in patients under interferon alpha therapy whether responsive or non-responsive to therapy. Thirty chronic hepatitis C patients (CHC) under combined therapy of interferon-α with ribavirin, whether responsive or non-responsive, were included in the study as well as ten healthy controls. Serum... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: ICAM-1; VCAM-1; Interferon; Ribavirin; Chronic hepatitis C. |
| Ano: 2010 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1678-91992010000300010 |
| |
|
| |
|
|
| Andrade,Luis Jesuino de Oliveira; Atta,Ajax Mercês; Atta,Maria Luiza Brito de Sousa; Mangabeira,Célia Neder Kalil; Paraná,Raymundo. |
| OBJECTIVE: To investigate the frequency of thyroid disorders (TD) in patients with chronic hepatitis C before and during interferon-alpha (IFN-α) and ribavirin (RIB) treatment. STUDY DESIGN: Prospective study. PATIENTS AND METHODS: We prospectively studied 65 anti-HCV and viral RNA positive patients. Free thyroxine, thyroid-stimulating hormone, and thyroid peroxidase antibodies (TPO-Ab) were systematically tested at entry (m0), week 12 (m3) and week 24 (m6) of treatment. RESULTS: Mean age of the 65 patients (38 females and 27 males) was 49.61 ± 11.83 years. Seven (10.76%) patients presented baseline thyroid disorders (m0), three had thyroid dysfunction, and four were TPO-Ab positive. Thyroid disorders occurred in the first 12 weeks of treatment in 11... |
| Tipo: Info:eu-repo/semantics/other |
Palavras-chave: Hepatitis C; Interferon-alpha; Ribavirin; Thyroid diseases; Autoimmunity. |
| Ano: 2011 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000400013 |
| |
|
| |
|
| |
|
| |
|
|
| Parise,E.; Cheinquer,H.; Crespo,D.; Meirelles,A.; Martinelli,A.; Sette,H.; Gallizi,J.; Silva,R.; Lacet,C.; Correa,E.; Cotrim,H.; Fonseca,J.; Paraná,R.; Spinelli,V.; Amorim,W.; Tatsch,F.; Pessoa,M.. |
| Peginterferon alfa plus ribavirin is currently the treatment of choice for chronic hepatitis C. Peginterferon alfa-2a (40KD) plus ribavirin has given an overall sustained virological response of 18% in F3/F4 previous nonresponder US patients. We evaluated the effectiveness of peginterferon alfa-2a (40KD) plus ribavirin in Brazilian patients who were relapsers or nonresponders to previous interferon-based therapy. One-hundred-thirty-four patients with biopsy-proven chronic hepatitis C, HCV RNA positive, elevated ALT and who were either relapsers (n=37) or nonresponders (n=97) to at least 24 weeks of conventional interferon/ribavirin therapy were retreated with peginterferon alfa-2a (40KD) 180mg/qw and ribavirin 800mg bid for 48 weeks. Efficacy was assessed... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Peginterferon alfa; Ribavirin; Hepatitis C; Safety; Efficacy. |
| Ano: 2006 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702006000100003 |
| |
|
|
| Lopes,Edmundo P.A.; Valente,Lucila M.; Silva,A. Eduardo B.; Kirsztajn,Gianna Mastroianni; Cruz,Cibele N.; Ferraz,Maria Lucia G. |
| We describe a treatment made with interferon-alpha (IFN-alpha) plus ribavirin of two patients with membranoproliferative glomerulonephritis (MPGN) induced by hepatitis C virus (HCV): Case 1 was a 22-year-old woman with leg and facial edema, hypertension and proteinuria, whose liver biopsy revealed chronic active hepatitis; and Case 2 was a 42-year-old man with anasarca, hypertension and proteinuria, whose liver biopsy indicated cirrhosis. Both had anti-HCV, HCV-RNA and cryoglobulins. IFN-alpha (3 million units (MU), 3 times/week) and ribavirin (1 g/day) were administered for 12 months. The drugs were well tolerated by both patients. Serum alanine aminotransferase (ALT) levels normalized and HCV-RNA became negative. Cryoglobulins disappeared and an... |
| Tipo: Info:eu-repo/semantics/report |
Palavras-chave: Glomerulonephritis; Hepatitis C; Interferon; Ribavirin. |
| Ano: 2003 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702003000500011 |
| |
|
|
| Sabbatani,Sergio; Giuliani,Ruggero; Manfredi,Roberto. |
| The elevated frequency of chronic hepatitis C virus (HCV) infection found among prison inmates, and the availability of improved pharmacological cure for this potentially life-threatening disorder, make investigations conducted in this somewhat neglected area very relevant, since only a few, open-label experiences have been reported till now. In the metropolitan prison of Bologna (Italy), HCV seroprevalence was found to be over 31% in 2003, so that a pilot feasibility study based on treatment with pegylated interferon plus ribavirin was initiated, after careful counseling carried out by a joint commission of health care personnel of the correctional facility and infectious diseases consultants. Thirty-nine patients were enrolled, and despite expected... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Chronic hepatitis C; Pegylated interferon; Ribavirin; Management; Inmates; Prison. |
| Ano: 2006 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702006000400012 |
| |
|
|
| Prado,Kleber; Patzina,Rosely; Bergamaschi,Denise; Focaccia,Roberto. |
| Chronic hepatitis C is often a progressive, fibrotic disease that can lead to cirrhosis and other complications. The recommended therapy is a combination of interferon and ribavirin. Besides its antiviral action, interferon is considered to have antifibrotic activity. We examined the outcome of hepatic fibrosis and inflammation in chronic hepatitis C patients who were non-responders to interferon. We made a case series, retrospective study, based on revision of medical records and reassessment of liver biopsies. For inclusion, patients should have been treated with interferon alone or combined with ribavirin, with no virological response (non responders and relapsers) and had a liver biopsy before and after treatment. Histological evaluation included:... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Chronic hepatitis C; Fibrosis; Interferon-alfa; Ribavirin; Treatment result. |
| Ano: 2008 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702008000500004 |
| |
|
| |
|
|
| Vigani,A.G.; Macedo-de-Oliveira,A.; Pavan,M.H.P.; Pedro,M.N.; Gonçales Jr.,F.L.. |
| Hepatitis C virus (HCV) is essentially hepatotropic but its manifestations can extend beyond the liver. It can be associated with autoimmune diseases, such as mixed cryoglobulinemia, membranoproliferative glomerulonephritis, autoimmune thyroiditis, and lymphoproliferative disorders. The mechanisms that trigger these manifestations are not completely understood. We describe a 48-year-old man with chronic HCV infection (circulating HCV RNA and moderate hepatitis as indicated by liver biopsy), cryoglobulinemia, and sensory and motor peripheral neuropathy. The diagnosis of multineuropathy was confirmed by clinical examination and electromyographic tests. A nerve biopsy revealed an inflammatory infiltrate in the perineurial space and signs of demyelination and... |
| Tipo: Info:eu-repo/semantics/report |
Palavras-chave: Hepatitis C virus; Neurological manifestations; Cryoglobulins; Interferon; Ribavirin. |
| Ano: 2005 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005001200001 |
| |
|
|
| Zanaga,L.P.; Miotto,N.; Mendes,L.C.; Stucchi,R.S.B.; Vigani,A.G.. |
| Hepatitis C virus (HCV) genotype 3 is responsible for 30.1% of chronic hepatitis C infection cases worldwide. In the era of direct-acting antivirals, these patients have become one of the most challenging to treat, due to fewer effective drug options, higher risk of developing cirrhosis and hepatocellular carcinoma and lower sustained virological response (SVR) rates. Currently there are 4 recommended drugs for the treatment of HCV genotype 3: pegylated interferon (PegIFN), sofosbuvir (SOF), daclatasvir (DCV) and ribavirin (RBV). Treatment with PegIFN, SOF and RBV for 12 weeks has an overall SVR rate of 83–100%, without significant differences among cirrhotic and non-cirrhotic patients. However, this therapeutic regimen has several contraindications and... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Hepatitis C treatment; Genotype 3; Sofosbuvir; Daclatasvir; Ribavirin. |
| Ano: 2016 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016001100302 |
| |
| Registros recuperados: 13 | |
|
|
|
